A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations

Yanan Zhao; Annie Lee; Kaelea Composto; Marcus H. Cunningham; Jose R. Mediavilla; Samantha Fennessey; André Corvelo; Kar Fai Chow; Michael Zody; Liang Chen; Barry N. Kreiswirth; David S. Perlin

doi:10.1080/22221751.2021.1929504

A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations

Yanan Zhao, Annie Lee, Kaelea Composto, Marcus H. Cunningham, Jose R. Mediavilla, Samantha Fennessey, André Corvelo, Kar Fai Chow, Michael Zody, Liang Chen, Barry N. Kreiswirth, David S. Perlin

Hackensack Meridian School of Medicine, Rutgers, The State University

Research output: Contribution to journal › Letter › peer-review

Abstract

Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants are lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 1135 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey between late December 2020 and March 2021. Our data revealed dramatic increases in the frequencies of both E484K and N501Y over time, underscoring the need for continuous epidemiological monitoring.

Original language	English
Pages (from-to)	994-997
Number of pages	4
Journal	Emerging Microbes and Infections
Volume	10
Issue number	1
DOIs	https://doi.org/10.1080/22221751.2021.1929504
State	Published - 2021

ASJC Scopus subject areas

Parasitology
Epidemiology
Microbiology
Immunology
Drug Discovery
Virology
Infectious Diseases

Keywords

E484K
N501Y
SARS-CoV-2
molecular assay
screening
variants

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/22221751.2021.1929504

Cite this

@article{6c0ab93ce6e54fd68bfef1d82057f17e,

title = "A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations",

abstract = "Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants are lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 1135 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey between late December 2020 and March 2021. Our data revealed dramatic increases in the frequencies of both E484K and N501Y over time, underscoring the need for continuous epidemiological monitoring.",

keywords = "E484K, N501Y, SARS-CoV-2, molecular assay, screening, variants",

author = "Yanan Zhao and Annie Lee and Kaelea Composto and Cunningham, {Marcus H.} and Mediavilla, {Jose R.} and Samantha Fennessey and Andr{\'e} Corvelo and Chow, {Kar Fai} and Michael Zody and Liang Chen and Kreiswirth, {Barry N.} and Perlin, {David S.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd.",

year = "2021",

doi = "10.1080/22221751.2021.1929504",

language = "English",

volume = "10",

pages = "994--997",

journal = "Emerging Microbes and Infections",

issn = "2222-1751",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations

AU - Zhao, Yanan

AU - Lee, Annie

AU - Composto, Kaelea

AU - Cunningham, Marcus H.

AU - Mediavilla, Jose R.

AU - Fennessey, Samantha

AU - Corvelo, André

AU - Chow, Kar Fai

AU - Zody, Michael

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Perlin, David S.

PY - 2021

Y1 - 2021

N2 - Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants are lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 1135 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey between late December 2020 and March 2021. Our data revealed dramatic increases in the frequencies of both E484K and N501Y over time, underscoring the need for continuous epidemiological monitoring.

AB - Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants are lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 1135 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey between late December 2020 and March 2021. Our data revealed dramatic increases in the frequencies of both E484K and N501Y over time, underscoring the need for continuous epidemiological monitoring.

KW - E484K

KW - N501Y

KW - SARS-CoV-2

KW - molecular assay

KW - screening

KW - variants

UR - http://www.scopus.com/inward/record.url?scp=85107014886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107014886&partnerID=8YFLogxK

U2 - 10.1080/22221751.2021.1929504

DO - 10.1080/22221751.2021.1929504

M3 - Letter

C2 - 33977858

SN - 2222-1751

VL - 10

SP - 994

EP - 997

JO - Emerging Microbes and Infections

JF - Emerging Microbes and Infections

IS - 1

ER -

A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this